---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002475"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T19:31:28.855302+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne invests $257M for 20% of Wilson Wolf; future buyout up to $1B

## Summary
- Wilson Wolf met trailing 12-month EBITDA target of $55M, triggering Bio-Techne's option.
- Bio-Techne will pay $257M for a 20% ownership stake; close expected end of March 2023.
- Remaining 80% can be acquired for $1B if Wilson Wolf hits $226M revenue or $136M EBITDA.
- If milestone not met by Dec 31, 2027, Bio-Techne can buy for ~4.4x trailing revenue.
- Wilson Wolf's G-Rex cell production tech is used by over 800 cell and gene therapy entities.

## SEC filing metadata
- accession: 0001558370-23-002475
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837023002475/0001558370-23-002475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837023002475/tmb-20230228x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002475
- JSON: https://secwatch.observer/filing/0001558370-23-002475.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.